Founded by the discoverer of SingulAir, Vioxx, Arcoxia, and ondanacatib while leading medicinal chemistry at Merck, Robert Young, created Mesentech to develop tissue selective prodrugs of *existing* compounds that were abandoned due to end-organ toxicity.
Mesentech's platform allows for rapid evaluation of bi-specific conjugate prodrugs that deliver the active pharmaceutical agent selectively to target tissue thereby eliminating toxicity and side effects caused by systemic exposure.
MES1007, now undergoing IND enabling, is a bone-targeted prodrug of an EP4 agonist. EP4 is a prostaglandin mimetic; prostaglandins were extensively researched by both Pfizer (CP532) and Merck for its potential to reverse pathological bone-loss caused by diseases like osteoporosis; however, all members of that class suffered from systemic side-effects which impeded their development. MES1007 eliminated the systemic intolerability of EP4 agonists with demonstrated NOAEL in excess of 20X the parent compound.
We focus exclusively on compounds that underwent extensive characterization at large pharmaceutical firms but were abandoned due to systemic intolerance or specific end-organ tox. The conjugate prodrugs of these compounds are New Chemical Entities and enjoy composition of matter patents.
Mesentech's platform allows for rapid evaluation of bi-specific conjugate prodrugs that deliver the active pharmaceutical agent selectively to target tissue thereby eliminating toxicity and side effects caused by systemic exposure.
MES1007, now undergoing IND enabling, is a bone-targeted prodrug of an EP4 agonist. EP4 is a prostaglandin mimetic; prostaglandins were extensively researched by both Pfizer (CP532) and Merck for its potential to reverse pathological bone-loss caused by diseases like osteoporosis; however, all members of that class suffered from systemic side-effects which impeded their development. MES1007 eliminated the systemic intolerability of EP4 agonists with demonstrated NOAEL in excess of 20X the parent compound.
We focus exclusively on compounds that underwent extensive characterization at large pharmaceutical firms but were abandoned due to systemic intolerance or specific end-organ tox. The conjugate prodrugs of these compounds are New Chemical Entities and enjoy composition of matter patents.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2018
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
Bone-targeted anabolic compound for reversing bone-loss disease
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
